Oasis Semaglutide Weight Loss Program

What Is Semaglutide?

Semaglutide is a prescription drug recently approved by the FDA for weight loss in 2021. It has helped people lose 15-20% of their body weight. It is an injectable medication used in combination with diet and exercise to help with blood sugar control. It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) agonists, which mimic the hormone GLP-1 in your body to lower blood sugar levels after eating. GLP-1, the critical hormone involved, slows down how fast your stomach empties food (called gastric emptying). And in addition to causing your pancreas to release insulin, it also blocks a hormone that causes your liver to release sugar.

How Does Semaglutide work?

As a GLP1 it binds to a receptor in the gut that normally would be set off by ingesting food. This creates a sensation of satiety or fullness in the brain. It also decreases gastric emptying speed- so that food stays in your stomach longer. This increases insulin sensitivity (Insulin controls the amount of sugar in the blood by moving it into the cells, where it can be used by the body for energy) and decreases glucose production (glucose is the main type of sugar in the blood and is the major source of energy for the body's cells).

Benefits of Semaglutide
  • Reduced appetite

  • Improved eating control

  • Reduced food cravings

  • Improved glycemic control

  • Blood sugar-lowering effects without lowering blood sugar

  • Reduced body weight, cholesterol, blood pressure, inflammatory markers, and oxidative stress

  • Reduced cardiovascular risk factors such as BMI and waist circumference

  • Improved health and longevity of patients suffering from obesity-related illnesses such as Type 2 Diabetes

  • Decreased dependency on medications to lower blood sugar in patients with Type 2 Diabetes

  • Improved breathing and sleep in patients with sleep apnea

  • NAFLD (Non-alcoholic Fatty Liver Disease) and NASH (Nonalcoholic Steatohepatitis) were  improved or reversed in 59% 

The Bottom Line
semaglutide 1.png